Connection

Oliver Cornely to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Oliver Cornely has written about Treatment Outcome.
Oliver Cornely
Connection Strength
0.242
Treatment Outcome
  1. Baseline predictors influencing the prognosis of invasive aspergillosis in adults. Mycoses. 2019 Aug; 62(8):651-658.
    View in: PubMed
    Score: 0.029
  2. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses. Eur J Clin Microbiol Infect Dis. 2019 Jun; 38(6):1187-1194.
    View in: PubMed
    Score: 0.029
  3. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®. Crit Rev Microbiol. 2019 Feb; 45(1):1-21.
    View in: PubMed
    Score: 0.029
  4. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged =60 years (EXTEND): analysis of cost-effectiveness. J Antimicrob Chemother. 2018 09 01; 73(9):2529-2539.
    View in: PubMed
    Score: 0.028
  5. Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 2018 Aug; 61(8):518-533.
    View in: PubMed
    Score: 0.028
  6. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother. 2017 08 01; 72(8):2359-2367.
    View in: PubMed
    Score: 0.026
  7. Improving outcome of fungal diseases - Guiding experts and patients towards excellence. Mycoses. 2017 Jul; 60(7):420-425.
    View in: PubMed
    Score: 0.026
  8. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. Lancet Infect Dis. 2019 03; 19(3):265-274.
    View in: PubMed
    Score: 0.007
  9. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. Mycoses. 2018 Nov; 61(11):868-876.
    View in: PubMed
    Score: 0.007
  10. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents. 2018 Nov; 52(5):706-712.
    View in: PubMed
    Score: 0.007
  11. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses. 2018 Jul; 61(7):485-497.
    View in: PubMed
    Score: 0.007
  12. Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. J Antimicrob Chemother. 2018 03 01; 73(3):757-763.
    View in: PubMed
    Score: 0.007
  13. Fusarium Keratitis in Germany. J Clin Microbiol. 2017 10; 55(10):2983-2995.
    View in: PubMed
    Score: 0.006
  14. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016 Jul; 16(7):828-837.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.